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Healthcare utilisation databases, and other secondary data sources, have been used with growing frequency to 
assess health outcomes and healthcare interventions worldwide. Their increased popularity as a research tool 
is due to their timely availability, the large patient populations covered, low cost, and applicability for studying 
real-world clinical practice. Despite the need to measure Italian National Health Service performance both at 
regional and national levels, the wealth of good quality electronic data and the high standards of scientific 
research in this field, healthcare research and public health policies seem to progress along orthogonal 
dimensions in Italy. The main barriers to the development of evidence-based public health include the lack 
of understanding of evidence-based methodologies by policy makers, and of involvement of researchers in 
the policy process. The CRACK programme was launched by some academics from the Lombardy Region. By 
extensively using electronically stored data, epidemiologists, biostatisticians, pharmacologists and clinicians 
applied methods and evidence to several issues of healthcare research. The CRACK programme was based 
on their intention to remove barriers that thwart the process of bridging methods and findings from scientific 
journals to public health practice. This paper briefly describes aim, articulation and management of the CRACK 
programme, and discusses why it might find articulated application in Italy.
Key words: Comparative Effectiveness Research; Healthcare Utilization Database; Medical records; Evidence-
based public health
(1) Department of Statistics and Quantitative Methods, 
Division of Biostatistics, Epidemiology and Public Health, 
University of Milano-Bicocca, Milan, Italy
(2) Centre for Public Health, University of Milano-Bicocca, 
Milan, Italy
(3) Department of Epidemiology, IRCCS Istituto di Ricerche 
Farmacologiche “Mario Negri”, Milan, Italy
(4) Department of Clinical Sciences and Community Health, 
University of Milan, Milan, Italy
(5) Centro di Ricerca Interuniversitario per i Servizi di Pubblica 
Utilità (CRISP), University of Milano-Bicocca, Milan, Italy
(6) Department of Pharmacological Sciences, University of 
Milan, Milan, Italy
(7) Centre for Pharmacoepidemiology and 
Pharmacoutilisation, University of Milano, Milan, Italy
(8) IRCCS Istituto Auxologico Italiano, Milan, Italy
(9) Centre for Clinical Physiology and Hypertension, 
University of Milano-Bicocca, Milan, Italy
(10) Italian College of General Practitioners, Italy, Health 
Search, Florence, Italy
(11) Family Paediatrician Pedianet Project, Padua, Italy
(12) Operative Unit of Territorial Health Services, Lombardy 
Regional Administration, Milan, Italy
(13) Unit of Health Management, Italian Ministry of Health, 
Rome, Italy
(14) Centre for Epidemiology, Biostatistics and Medical Information 
Technology, Polytechnic University of Marche, Ancona, Italy
Corresponding author: Giovanni Corrao, 
Department of Statistics and Quantitative Methods, Division 
of Biostatistics, Epidemiology and Public Health, University of 
Milano-Bicocca, Via Bicocca degli Arcimboldi, 8, Building U7, 
20126 Milan, Italy. Tel: +39 02 64485854.
Fax: +39 02 64485899. e-mail: giovanni.corrao@unimib.it
doi: 10.2427/8980
e 8 9 8 0 - 1
OR IG INA L  AR T I C L ES
Epidemiology Biostatistics and Public Health - 2013, Volume 10, Number 3
BR IDG ING  HEA LTHCARE  RESEARCH  AND  PuBL I C  HEA LTH  POL I C I ES
FRom BIg DATA To CompARATIve 
eFFeCTIveNeSS ReSeARCH
The amount of data being digitally collected 
and stored is vast and rapidly expanding. 
Computer scientists introduced the term “big 
data” to describe this evolving technology. Big 
data has been successfully used in astronomy 
(e.g., the Sloan Digital Sky Survey of information 
provided by the telescope), retail sales (e.g., 
Walmart’s expansive number of transactions), 
search engines (e.g., Google’s customisation 
of individual searches based on previous web 
data), and politics (e.g., a campaign’s focus 
of political advertisements on people most 
likely to support their candidate based on web 
searches) [1].
In this paper we discuss the potential of 
big data in the field of healthcare research. 
Healthcare databases are attractive because 
they put large quantities of data into our hands. 
But let us be ready to say no to quantity if the 
quality impairment is too great. Both Weiss 
[2] and Ray [3] provide examples in which 
debatable eligibility criteria, incompleteness 
or incorrectness of linkage variables and 
ascertainment of exposure and outcome, and 
presence of confounding, resulted in incorrect 
conclusions.
We already pointed out that big data 
generated from healthcare utilisation databases 
and other secondary data sources should be 
regarded not only as a technological tool for 
storing and managing said data, but also, 
perhaps mainly, as a methodological challenge 
for building reliable evidence, which means 
converting data into information and know-
how to facilitate healthcare decision-making. 
Comparative effectiveness research is the 
answer to this demand [4, 5], and extraordinary 
methodological advancements on this issue 
have been achieved during the past few 
decades [6-12].
CompARATIve eFFeCTIveNeSS 
ReSeARCH FoR HeALTHCARe 
mANAgemeNT: LeSSoNS FRom THe US 
AND THe UK
In the United States, in the UK, as well 
as in many others countries, decisions based 
on the principles of evidence-based healthcare 
have guided healthcare practice, education, and 
policy for over 25 years [13]. The core principle 
of evidence-based healthcare is that decisions 
should be made using the best available 
scientific evidence [14].
In many cases, there may be a gradient of 
actions that could be taken based on available 
evidence. Quanstrum & Hayward discussed 
this gradient and argued that healthcare 
decision-making is changing, mainly because 
more information is available about treatment 
options [15]. In such conditions, decisions 
on healthcare treatment cannot be based on 
a threshold above which treatment is always 
considered beneficial and recommendable. 
Rather, there is almost always a large zone 
of choice where health benefits of a given 
treatment may be high and economically 
sustainable for a given population, but this 
might not be the case for other ones. This 
makes the decision-making process more 
complex than a “simple” evidence-based 
algorithm. In other words, the critical appraisal 
of all relevant research, as done in a systematic 
review of literature, is always necessary to 
make decisions [16, 17] because we must 
know whether a given treatment is expected 
to generate health benefits according to the 
best available knowledge. This knowledge is, 
however, often inadequate because it does 
not specify the impact of that treatment under 
the usual circumstances of healthcare practice. 
This justifies the great consideration gained 
by comparative effectiveness research during 
the last few decades as a key healthcare 
management tool.
Perhaps, the main evidence of this is the 
fact that comparative effectiveness research 
has been enshrined in the US Healthcare 
Reform Law of 2010 [18, 19]. The law 
mandates the creation of a Patient-Centred 
Outcomes Research Institute (PaCORI), which 
will establish national research priorities and 
methodological standards, and will carry out 
research. The UK’s National Institute for 
Health and Clinical Excellence, which was 
established in 1999, was the world pioneer 
in this area [20]. Though the organisational 
structure and duties of the American and 
British Institutes vary (e.g., the US Institute 
is barred by law from considering the cost-
effectiveness of interventions), both institutes 
have an overarching common goal: to improve 
public health through research on the relative 
effectiveness of different interventions [1].
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BRIDgINg HeALTHCARe ReSeARCH AND 
pUBLIC HeALTH poLICIeS: AN ITALIAN 
oUTLooK
There are at least three good reasons to 
consider Italy an ideal country for experiencing 
structured initiatives bridging healthcare 
research and public health policies. 
In the first place, the Italian National Health 
Service (NHS) provides universal coverage 
entitling all citizens to equal access to “essential” 
healthcare services, which are provided either 
free of charge or at a minimal charge  [http://
www.salute.gov.it/portale/salute/p1_5.jsp?ling
ua=italiano&id=111&area=Il_Ssn]. The NHS is 
structured into three hierarchical tiers of public 
authority: central government, regions, and 
local health authorities, namely geographically 
based health management organisations 
responsible for providing comprehensive 
care to a defined population [21]. The Italian 
Constitution (Art. 117) and the following 
legislative decrees [e.g., D.Lgs Sept, 18 2001, 
n.347 http://www.trovanorme.salute.gov.it/det
taglioAtto?id=12119&completo=true], assign 
the central government the duty of defining 
“essential” healthcare services, which must be 
warranted to all citizens [http://www.salute.
gov.it/portale/salute/p1_5.jsp?lingua=italiano&
id=111&area=Il_Ssn] and of monitoring use 
and impact of healthcare supplied and equity 
in access to healthcare services throughout 
Italy. The same laws decree that service 
management, healthcare services supplied and 
resource allocation must be wholly warranted 
to Regional Administrations for autonomous 
management. This implies the central 
government and regional authorities’ need for 
data, information and evidence to differentiate 
the decision-making process by competent 
territorial level and specific function.
Secondly, population-based secondary data 
sources have proliferated in Italy during the past 
few decades. Among these, regional healthcare 
utilisation databases that collect data for 
healthcare delivery system management would 
be a valuable resource for healthcare research. 
These are resources that many US health policy 
and health service researchers would like to 
find in their own country [22]. In fact, unlike 
US administrative databases, electronic archives 
used by the Italian healthcare system offer 
non-fragmented coverage of practically all 
the resident population. In addition, Italian 
healthcare utilisation databases have now 
reached a degree of completeness and quality 
that enhances the potential of that data and 
interest in the same to build reliable evidence 
in the field of comparative healthcare research.
Besides healthcare utilisation databases, 
enterprises networking general practitioners 
to create research-oriented medical records 
databases is a consolidated practice in Italy 
today. The most prominent among these, the 
so-called Thales - Health Search database 
(i.e., the Italian analogue of the British 
GPRD), receives data from more than 700 
general practitioners (GP) and covers almost 
2.1% of the Italian population [http://www.
healthsearch.it]. Other GP databases covering 
smaller populations provide very high quality 
data (e.g., the ULNet database that currently 
receives data from approximately 220 GPs 
operating in the Lombardy Region). In addition, 
the so-called Pedianet database [http://www.
pedianet.it/it/] is, to our knowledge, the only 
initiative in the world that, by networking 
almost 300 paediatricians of first choice (the 
general practitioner assisting children aged 
under 18 years in Italy), has created a very 
useful and unique paediatric database.
In such conditions, rather than contrasting 
North American and European approaches 
to real-world (RW) data collecting [23, 24] 
respectively by administrative databases (e.g., 
Medicare and Medicaid [25]) and medical records 
electronic archives (e.g., UK General Practice 
Research Database [26]), the coverage of large 
portions of the Italian population by both 
these sources allows their use and integration, 
augmenting the available informative potential.
Thirdly, it is an established fact that 
biostatisticians and epidemiologists are the 
natural comparative effectiveness researchers; 
for example, the 2010 US law establishes 
that the Board of Governors of the Institute 
shall collectively have scientific expertise in 
“epidemiology and biostatistics, other than in 
other scientific fields [27]. In Italy, there is a 
long and well-established academic tradition in 
these fields and many researchers are currently 
involved in methodological and applicative 
projects focused on using electronic databases 
as a tool for generating reliable evidence.
Despite the need to measure Italian 
National Health Service performance both at 
regional and national levels, the wealth of 
good quality electronic data and the high 
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standards of scientific research in this field, 
healthcare research and public health policies 
seem to progress along orthogonal dimensions 
in Italy. The main perceived barriers to the 
development of evidence-based public health 
in Italy, as well as in many European countries, 
include the lack of understanding of evidence-
based methodologies by policy makers [28] 




CRACK is the acronym of Carry out a 
Repository for Administrative and Clinical data 
Knotting. The idea is to create a data repository 
through the integration of different data sources 
to address open questions in the framework 
of important diseases for clinics and public 
health by underpinning the decision-making 
process with the principles of evidence-based 
healthcare. From this perspective, CRACK is 
both a technological platform and a basic 
infrastructure bridging healthcare research 
and public health policies.
It should be emphasised that, although the 
acronym CRACK uses the term repository, it does 
not imply the transfer of data from the place 
where they are stored by their owners (e.g., 
Regional authority or Italian Society of General 
Medicine) to a single storage site. Instead, the 
CRACK programme proposes collecting data 
from several sources according to a specific 
protocol that is approved by the regional 
authority and the scientific board (Figure 1). 
The questions we would like to answer through 
the use of the repository are related to the 
incidence and prognosis of diseases (prevalence, 
incidence, survival), healthcare utilisation 
patterns and safety, effectiveness and cost-
effectiveness profiles in RW clinical practice.
Both, general methodological issues and 
specific clinical and public health questions 
will be investigated to enhance the value of 
regional health data by exploiting them from 
the decision- maker’s point of view. In other 
words, the main strategic aim of the CRACK 
programme is to create a flywheel, which 
allows the regional authority to obtain solid 
data and strong evidence to address health 
policies.
The term “flywheel” is justified by the 
fact that both healthcare authorities and 
research teams would benefit from the CRACK 
programme because the former would obtain 
a “no-cost” tool for addressing health policies, 
while the latter would find good-quality health 
data available for scientific purposes. Finally, 
the CRACK programme is expected to boost 
methodological and applicative research in the 
field of comparative effectiveness research. 
Accordingly, training courses will be carried 
out within the CRACK programme.
Starting up the CRACK programme
The CRACK programme has been developed 
in the Lombardy Regional environment, which is 
not by chance. A wide and articulated system of 
HCU databases supporting management of the 
regional health service has been developed in 
Lombardy since 1997. Databases include:
• the archive of residents receiving regional 
health assistance, practically the whole 
resident population of about ten million 
inhabitants, or 16% of the Italian population;
• the HCU databases common to all Italian 
regions for reimbursement of health service 
providers (i.e., diagnostic information 
about hospital discharge from public or 
private hospitals and outpatient drug 
prescriptions reimbursable by the NHS);
• a single extensive recording system of 
health services, such as those concerning 
access to outpatient specialist and 
laboratory benefits, mental health services, 
emergency rooms, delivery assistance, 
vaccinations, among others.
Data may be linked together by using 
a unique identification code. In order to 
preserve privacy, the Lombardy Regional 
Administration and Privacy Authority agreed 
to the systematic conversion of the patient’s 
identification code (i.e., the tax code) into an 
anonymous “encrypted” code. This process 
prevents the possibility of identifying patients 
to whom health services are supplied (thus 
overcoming privacy barriers), while at the same 
time allowing recognition of each single citizen 
along his or her entire health track (providing 
data for healthcare research).
The wide availability of population-based 
medical record data, such as:
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• the above reported ULNet general 
practitioners network,
• and the Lombardy portion of Health 
Search and Pedianet databases;
and disease registries, such as:
• the six cancer registers of Varese, Milan, 
Brescia, Como, Mantua and Sondrio 
accredited by the Italian Association of 
Cancer Registries [http://www.registri-
tumori.it/cms/?q=node/21#];
• and the WHO-MONICA registry of ischemic 
heart disease and cerebrovascular disease 
covering the population resident in the 
Brianza area [30]),
make the Lombardy Region particularly 
attractive for conducting healthcare research 
based on the use of electronically stored data.
CRACK was launched by some academics 
from the Lombardy Region. By extensively using 
electronically stored data, epidemiologists, 
biostatisticians, pharmacologists and clinicians 
applied methods and evidence to several issues 
of healthcare research [see references # 31-69 
for papers published in the past 12 months 
on these issues by the scientific board of the 
CRACK programme]. The CRACK programme 
was based on their intention to remove barriers 
that thwart the process of bridging methods 
and findings from scientific journals to public 
health practice. Concise information on its aims, 
articulation, management and perspectives is 
supplied in the following paragraphs.
Aims
The main strategic aim of the CRACK 
programme is to create a technologic platform 
and a basic infrastructure that allows regional 
authorities to obtain solid data and strong 
evidence to address health policies. The 
CRACK programme is also expected to boost 
methodological and applicative research in the 
field of comparative effectiveness research.
The implementation of a repository of 
administrative (HCU) and clinical (MR) electronic 
data covering a given territorial unit (e.g., NHS 
beneficiaries resident in the Lombardy Region) 
will be functional to investigate:
• methodological issues: e.g., 
recognise the sources of systematic 
uncertainty (mainly misclassification 
and confounding) when HCU and 
MR data are used separately, and 
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implement methods for controlling 
and/or minimising the effect of such 
biases by means of integrating HCU 
and MR data;
• clinical areas: i.e., the management 
of conditions and diseases that are 
particularly important for public health 
(e.g., heart failure, hypertension, 
dyslipidaemia, type 2 diabetes, cancer, 
chronic obstructive pulmonary disease, 
psychiatric, geriatric and paediatric 
diseases, among others) in RW clinical 
practice by: (i) assessing the care 
tracks of patients who start drug 
therapy for a given condition/disease 
(including heterogeneity in therapeutic 
profiles and refill compliance with 
drug therapies) based on their socio-
demographic and clinical features; (ii) 
estimating the association between 
care tracks of patients who start drug 
therapy for a given condition/disease 
and their risk of experiencing selected 
clinical outcomes; (iii) providing for 
cost-effectiveness estimates of care 
tracks;
• health econometrics and health 
demand: i.e., providing comprehensive 
analyses of demand/supply profiles 
and measuring the level of healthcare 
quality and expenditure.
Finally, the CRACK programme is expected 
to facilitate bridging with other European and 
extra-European countries with the subsequent 
creation of consortiums that are functional to 
access research findings.
Articulation
Four working packages form the bearing 
wall of CRACK architecture.
First, methodological standards for creating 
the technological platform that underpins the 
entire programme, including statistical software 
for data drawing, linking and modelling, are 
the objective of the methodological working 
package. It must be said that CRACK does 
not imply the development of a single data 
container, but rather data collection from 
several sources according to a specific protocol 
approved by the regional authority and the 
scientific board. This will be achieved by 
carrying out, maintaining and updating an 
integrated system useful to (a) collect data from 
different and heterogeneous sources; (b) extract 
fields according to their relevance for the study 
objective, and select records according to 
predefined inclusion and exclusion criteria; (c) 
link records according to a specific procedure; 
(d) organise such data to allow implementation 
of several observational designs; (e) place such 
data according to conventional and emerging 
statistical models; (f) investigate the robustness 
of findings by varying criteria applied to 
principal analyses and fitting different models 
of sensitivity analysis.
Second, the patient-centred investigation 
of conditions and disease management in the 
RW clinical practice will constitute the objective 
of the clinical working package. This package 
will be articulated in clinical areas (e.g., 
cardiovascular, respiratory and gastrointestinal 
diseases, diabetes, oncology, mental health, 
geriatrics, paediatrics, environmental health 
and drug safety) and, among these, in specific 
research projects (e.g., exploring the impact of 
prescribing and substituting generic drugs: the 
example of cardiovascular therapies; measuring 
the healthcare burden of diabetes mellitus; 
clinical use, safety and effectiveness of novel 
high cost anticancer therapies after marketing 
approval: a record linkage study).
Third, the service-centred investigation 
on healthcare system performance (e.g., 
appropriateness, quality, efficacy and 
efficiency) and its financial stability will 
constitute the objective of the healthcare 
management working package. This package 
will be articulated in specific research projects 
(e.g., administrative databases as a tool for 
identifying healthcare demand and costs in a 
population of over one million).
Finally, with the aim of transferring 
methods for comparative effectiveness 
research to NHS staff employed for healthcare 
database management, as well as to healthcare 
researchers, the implementation of this 
educational working package is the basic 
condition for the success of the CRACK 
programme. There is actually a great need: 1) 
of knowledge and competencies in this field 
of research; 2) of standardised methods to 
guarantee good research practice in the field 
of observational studies; 3) for healthcare 
research and public health policies to start 
speaking common languages and use common 
methods, thus moving beyond barriers for the 
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development of evidence-based public health 
in Italy. With this objective, residential courses 
will be held on: 1) observational methods (e.g., 
measures, random and systematic uncertainty, 
study designing, meta-analysis); 2) biostatistics 
for epidemiologists (e.g., basic methods and 
advanced techniques); 3) informative systems 
for the management of healthcare utilisation 
databases that are useful for comparative 
effectiveness research; 4) writing research 
protocols and technical reports.
management
Management of the CRACK programme will 
be assured by two entities that are independent 
from NHS authorities, as well as from industry 
pressures, in order to ensure the absence of 
any conflict of interest.
The first entity is the scientific board, 
which include academic members who are 
experienced in the field of research methodology 
(epidemiologists and biostatisticians), public 
health, medicine and pharmacology. The 
scientific board would cooperate with public 
healthcare authorities: 1) in selecting the 
priority fields, which would be investigated 
to improve healthcare management; 2) in 
evaluating research protocols by considering 
their scientific quality, as well as their 
relevance in the decision-making process; 3) in 
coordinating working package activities; 4) in 
communicating results of healthcare research 
carried out with administrative databases, with 
the aim of encouraging the transfer of healthcare 
research to public health policies. The scientific 
board will include a small number of fixed 
members and a variable number of members 
who will be co-opted for the management of 
specific projects. Emphasis would be given 
to the absence of conflicting interests and to 
documented scientific experience in the field of 
comparative effectiveness research, especially 
of fixed members of the scientific board.
The second entity is the network of 
accredited laboratories for data treatment 
in the fields of competence of the CRACK 
programme. Accrediting a laboratory means 
that it must guarantee conformity to: 1) Italian 
rules for treatment of sensitive data [70]; 2) 
recommendations for good research practices 
for retrospective databases to be designed 
and analysed by the International Society for 
Pharmacoeconomics and Outcomes Research 
(ISPOR) [6-8], as well as by a specific paper of 
the current issue of EBPH entitled “Building 
reliable evidence from real- world data: 
methods, cautiousness and recommendations” 
[71]. Additionally, regular auditing ensures that 
confidentiality and good research practice are 
both guaranteed by accredited laboratories.
pRoSpeCT
The CRACK programme was conceived 
and developed in Lombardy, but its structure 
is clearly suitable for any Italian Region. 
However, its most interesting application and 
intriguing challenge should be at the national 
level.
A distinguishing feature of the Italian NHS 
is that individual Regions are autonomous in 
healthcare management, including resource 
allocation. There is however the need to ensure 
equal quality and access in healthcare services 
across the Nation. This last is a priority for Health 
Ministry. It involves evaluation and comparison 
of regional health system performances, using a 
set of validated indicators based on national data 
flows, followed by national recommendations 
and guidelines aimed to improve regional 
health system performances.
National hospital discharge databases have 
been the main source of health information 
for a long time. However, in the last few years 
healthcare focus has shifted from hospital 
to outpatient settings. Patients are kept as 
long as possible in their own environment, 
and transitional care is improved to avoid 
hospitalization. This entails that additional 
information is needed to assess health service 
performances besides hospitalization and other 
health events. Over the last three years new 
national data flows have been activated to 
achieve this goal, but their optimization is 
heavily influenced by variability of regional 
databases.
As discussed above, comparative research 
is critical to devise interventions aimed to 
improve healthcare quality and efficiency.
Due to variability of regional healthcare 
systems in Italy, two main aims need to be 
pursued. The first is enhancing comparative 
effectiveness research in each Italian region. 
The second aim is obtaining comparable results 
in different Regions.
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Through implementation of the CRACK 
programme, the Ministry of Health could 
provide each Italian region with three important 
tools to improve healthcare system quality and 
equity.
The first tool is an equal-for-all, 
standardized methodology to integrate regional 
healthcare databases, to obtain validated and 
comparable performance indicators. Thus, it 
should be possible to integrate the national set 
of indicators with information that is difficult, 
impossible or too expensive to collect through 
a national data flow. On the other hand, the 
shared methodology provides useful data to 
improve completeness and quality of active and 
future NHS data flows.
The second tool is an equal-for-all, 
standardized methodology to use regional 
healthcare databases to generate comparable 
data as well as solid scientific evidence to 
assess equity in healthcare service access 
and effectiveness, safety and sustainability of 
diagnostic-therapeutic journeys in RW clinical 
practice. This would enable regional authorities 
and national government to work together on 
the same data and to orient decisions towards 
evidence-based healthcare principles.
The third tool is the educational working 
package of the CRACK programme, which 
should help disseminate good comparative 
effectiveness research practices and correct use 
of research results methods among healthcare 
researchers and operators and among health 
policymakers at all NHS levels: local, regional 
and central government authorities.
The National Agency for Regional Health 
Services (AGENAS) is aimed to connect Health 
Ministry and Regions, supporting decision-
making on government policies in NHS 
strategies. The CRACK program could help 
optimize the joint action of the Health Ministry 
and AGENAS, supporting the evidence-based 
decision-making process and its adaptation to 
different NHS levels and functions.
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